Heat Biologics

HTBX NASDAQ
0.7800
+0.0288
+3.83%
Opening 13:03 06/19 EDT
Open
0.7500
Prev Close
0.7512
High
0.7800
Low
0.7500
Volume
83.50K
Avg Vol (3M)
325.61K
52 Week High
2.530
52 Week Low
0.6659
% Turnover
0.25%
Market Cap
26.57M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Heat Biologics HTBX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
MORE >

Recently

Name
Price
%Change